As part of it's initiative for expanded IP technology development, strategic partnering and licensing, PHIGENIX is pleased to announce that we have acquired the services of DLA Piper, LLP. Dr. Carlton D. Donald, President and CEO of PHIGENIX, commented, "Our meeting today with representatives of DLA Piper's Global Life Sciences team was both exciting and encouraging. Their proven track record and experience in counseling clients on strategic patent matters, including patent prosecution, product clearance, patent portfolio mapping, and patent mining evaluations and analyses will be instrumental in assisting Phigenix in reaching its goals." DLA Piper has been named “Game Changer of the Past 10 Years” by Financial Times (2015), and have 34 DLA Piper lawyers from 10 countries recognized as world’s leading patent practitioners by Intellectual Asset Management IAM Patent 1000 (2017), among other distinctions.
Phigenix appoints Mr. Michael C. Shores, who currently serves as Entrepreneur in Residence at Quark Ventures, to its Board of Directors. Dr. Carlton Donald, President and CEO of PHIGENIX, commented, “We are excited to welcome Michael Shores to the Board of Directors. He brings a wealth of experience across numerous sectors, including healthcare". Click here to download the press release.
The Morehouse College Entrepreneurship Center presented Dr. Carlton D. Donald with the Innovative Creative Entrepreneur (ICE) Small Business Award in Public Health. The ICE Awards recognize small businesses and visionary leaders who have championed the cause of minority business development and innovation.
Phigenix was profiled in the September 30, 2011 edition of the Atlanta Business Chronicle as part of their segment featuring "interesting new technologies developed by Georgia companies and researchers". The article stated that "Phigenix is seeking to patent a way to prevent or treat prostate cancer. The method inhibits the expression of the PAX2 gene". The article goes further to say that "Phigenix has also filed for a patent for a treatment for breast cancer. Learn more about Phigenix at http://phigenix.com".
In a recent study, Human beta defensin-1 (DEFB1) loss was observed in 95.6% of Gleason 3 and 90% of Gleason 4 biopsies, and it was concluded that DEFB1 loss is a useful indicator to identify patients with high risk of developing prostate cancer (Hong et al., APMIS. 2017 Sep 8). Phigenix is currently developing a DEFB1-based diagnostic test for prostate cancer.
It has been reported that an aptamer-based electrochemical biosensor has been developed which can detect EN2 at low levels for the detection of prostate cancer in urine (Settu et al., Anal Biochem. 2017 Oct 1;534:99-107). These finding will be instrumental in Phigenix developing its EN2 screening test and EN2-targeted therapy for prostate cancer.
Phigenix hires top patent firm Fish & Richardson, LLP to protect and enforce its ground-breaking patent portfolio covering novel therapeutics and diagnostics in prostate and breast cancer. Fish & Richardson was named #1 Top Patent Litigation Firm for 13th consecutive year by Corporate Counsel Magazine Click here to download the full survey.
On September 29, 2017, Bloombeg BNA News published an article written by Dana A. Elfin, which state "Atlanta-based Phigenix is a nonpracticing entity (NPE), which means it buys up patents and makes money from selling licenses for them. " This assessment is incorrect and mischaracterizes Phigenix and its corporate mission. Phigenix was formed in 2007 by Dr. Carlton Donald as a "spin-off" biotech company from the Medical University of South Carolina, where Dr. Donald was a clinical researcher, to further develop novel therapeutic compounds and companion diagnostics that he invented. Several publicly available resources describe Phigenix's research efforts in the area of Personalized Medicine. The Bloombeg article can be read here: https://www.bna.com/phigenix-seeks-undo-n73014470365/.